T1	AdverseReaction 54 83	Nephrogenic Systemic Fibrosis
T2	AdverseReaction 259 272;290 299	anaphylactoid reactions
T3	AdverseReaction 273 289;290 299	hypersensitivity reactions
T4	AdverseReaction 305 319;347 361	cardiovascular manifestations
T5	AdverseReaction 321 332;347 361	respiratory manifestations
T6	AdverseReaction 337 361	cutaneous manifestations
T7	Severity 376 380	mild
T8	Severity 384 390	severe
T9	AdverseReaction 411 416	shock
T10	DrugClass 568 600	Gadolinium-based contrast agents
T11	AdverseReaction 631 660	nephrogenic systemic fibrosis
T12	AdverseReaction 662 665	NSF
T13	AdverseReaction 899 902	NSF
T14	DrugClass 883 887	GBCA
T16	AdverseReaction 1256 1259	NSF
T17	Factor 1260 1263	may
T18	AdverseReaction 1274 1279	fatal
T19	AdverseReaction 1296 1304	fibrosis
T23	AdverseReaction 2166 2169	NSF
T24	Factor 2157 2161	risk
T25	AdverseReaction 2912 2924;2952 2961	Anaphylactic reactions
T26	AdverseReaction 2967 2981;3009 3023	cardiovascular manifestations
T27	AdverseReaction 2983 2994;3009 3023	respiratory manifestations
T28	AdverseReaction 2999 3023	cutaneous manifestations
T29	Severity 3038 3042	mild
T30	Severity 3046 3052	severe
T31	AdverseReaction 3064 3069	shock
T32	AdverseReaction 3606 3622;3699 3716	hypersensitivity Delayed reactions
T33	Factor 3717 3720	can
T34	DrugClass 4056 4061	GBCAs
T35	AdverseReaction 3968 3987	acute kidney injury
T36	Factor 4457 4460	may
T37	AdverseReaction 4304 4318;4471 4493	Injection Site local tissue reactions
T38	Factor 622 626	risk
T39	Factor 417 420	can
T20	AdverseReaction 2935 2961	hypersensitivity reactions
T21	AdverseReaction 3359 3384	hypersensitivity reaction
T22	Factor 3348 3352	risk
T40	Factor 4067 4071	risk
T41	AdverseReaction 4075 4094	acute kidney injury
T42	Severity 1283 1295	debilitating
E1	AdverseReaction:T1
E2	AdverseReaction:T2 Hypothetical:E39
E3	AdverseReaction:T3 Hypothetical:E39
E4	AdverseReaction:T4 Effect:E7 Effect2:E8 Hypothetical:E39
E5	AdverseReaction:T5 Effect:E7 Effect2:E8 Hypothetical:E39
E6	AdverseReaction:T6 Effect:E7 Effect2:E8 Hypothetical:E39
E7	Severity:T7
E8	Severity:T8
E9	AdverseReaction:T9 Hypothetical:E39
E10	DrugClass:T10
E11	AdverseReaction:T11 Hypothetical:E10
E12	AdverseReaction:T12 Hypothetical:E10
E13	AdverseReaction:T13 Hypothetical2:E14
E14	DrugClass:T14
E16	AdverseReaction:T16 Hypothetical:E17
E17	Factor:T17
E18	AdverseReaction:T18 Hypothetical:E17
E19	AdverseReaction:T19 Hypothetical:E17 Effect:E42
E23	AdverseReaction:T23 Hypothetical:E24
E24	Factor:T24
E25	AdverseReaction:T25
E26	AdverseReaction:T26 Effect:E29 Effect2:E30
E27	AdverseReaction:T27 Effect:E29 Effect2:E30
E28	AdverseReaction:T28 Effect:E29 Effect2:E30
E29	Severity:T29
E30	Severity:T30
E31	AdverseReaction:T31
E32	AdverseReaction:T32 Hypothetical:E33
E33	Factor:T33
E34	DrugClass:T34
E35	AdverseReaction:T35 Hypothetical:E34
E36	Factor:T36
E37	AdverseReaction:T37 Hypothetical:E36
E38	Factor:T38
E39	Factor:T39
E20	AdverseReaction:T20
E21	AdverseReaction:T21 Hypothetical:E22
E22	Factor:T22
E40	Factor:T40
E41	AdverseReaction:T41 Hypothetical:E40
E42	Severity:T42
A1	CUI E1 C3888044
A2	UMLS-Preferred-Name E1 Nephrogenic Systemic Fibrosis
A3	MEDDRA-PT E1 Nephrogenic systemic fibrosis
A4	MEDDRA-PT-ID E1 10067467
A5	CUI E2 C0340865
A6	UMLS-Preferred-Name E2 Anaphylactoid reaction
A7	MEDDRA-PT E2 Anaphylactoid reaction
A8	MEDDRA-PT-ID E2 10002216
A9	CUI E3 C0020517
A10	UMLS-Preferred-Name E3 Hypersensitivity
A11	MEDDRA-PT E3 Hypersensitivity
A12	MEDDRA-PT-ID E3 10020751
A13	LLT E3 Hypersensitivity reaction
A14	LLT-ID E3 10020756
A15	CUI E4 C0476270
A16	UMLS-Preferred-Name E4 Cardiovascular symptoms
A17	MEDDRA-PT E4 Cardiovascular symptom
A18	MEDDRA-PT-ID E4 10075534
A19	CUI E5 C0037090
A20	UMLS-Preferred-Name E5 Signs and Symptoms, Respiratory
A21	MEDDRA-PT E5 Respiratory symptom
A22	MEDDRA-PT-ID E5 10075535
A23	CUI E6 C0037285
A24	UMLS-Preferred-Name E6 Skin Manifestations
A25	MEDDRA-PT E6 Cutaneous symptom
A26	MEDDRA-PT-ID E6 10075531
A27	CUI E9 C0036974
A28	UMLS-Preferred-Name E9 Shock
A29	MEDDRA-PT E9 Shock
A30	MEDDRA-PT-ID E9 10040560
A31	CUI E11 C3888044
A32	UMLS-Preferred-Name E11 Nephrogenic Systemic Fibrosis
A33	MEDDRA-PT E11 Nephrogenic systemic fibrosis
A34	MEDDRA-PT-ID E11 10067467
A35	CUI E12 C3888044
A36	UMLS-Preferred-Name E12 Nephrogenic Systemic Fibrosis
A37	MEDDRA-PT E12 Nephrogenic systemic fibrosis
A38	MEDDRA-PT-ID E12 10067467
A39	CUI E13 C3888044
A40	UMLS-Preferred-Name E13 Nephrogenic Systemic Fibrosis
A41	MEDDRA-PT E13 Nephrogenic systemic fibrosis
A42	MEDDRA-PT-ID E13 10067467
A43	CUI E16 C3888044
A44	UMLS-Preferred-Name E16 Nephrogenic Systemic Fibrosis
A45	MEDDRA-PT E16 Nephrogenic systemic fibrosis
A46	MEDDRA-PT-ID E16 10067467
A47	CUI E18 C1306577
A48	UMLS-Preferred-Name E18 Death (finding)
A49	MEDDRA-PT E18 Death
A50	MEDDRA-PT-ID E18 10011906
A51	CUI E19 C0016059
A52	UMLS-Preferred-Name E19 Fibrosis
A53	MEDDRA-PT E19 Fibrosis
A54	MEDDRA-PT-ID E19 10016642
A55	CUI E23 C3888044
A56	UMLS-Preferred-Name E23 Nephrogenic Systemic Fibrosis
A57	MEDDRA-PT E23 Nephrogenic systemic fibrosis
A58	MEDDRA-PT-ID E23 10067467
A59	CUI E25 C0002792
A60	UMLS-Preferred-Name E25 anaphylaxis
A61	MEDDRA-PT E25 Anaphylactic reaction
A62	MEDDRA-PT-ID E25 10002198
A63	CUI E26 C0476270
A64	UMLS-Preferred-Name E26 Cardiovascular symptoms
A65	MEDDRA-PT E26 Cardiovascular symptom
A66	MEDDRA-PT-ID E26 10075534
A67	CUI E27 C0037090
A68	UMLS-Preferred-Name E27 Signs and Symptoms, Respiratory
A69	MEDDRA-PT E27 Respiratory symptom
A70	MEDDRA-PT-ID E27 10075535
A71	CUI E28 C0037285
A72	UMLS-Preferred-Name E28 Skin Manifestations
A73	MEDDRA-PT E28 Cutaneous symptom
A74	MEDDRA-PT-ID E28 10075531
A75	CUI E31 C0036974
A76	UMLS-Preferred-Name E31 Shock
A77	MEDDRA-PT E31 Shock
A78	MEDDRA-PT-ID E31 10040560
A79	CUI E32 C0020522
A80	UMLS-Preferred-Name E32 Delayed Hypersensitivity
A81	MEDDRA-PT E32 Type IV hypersensitivity reaction
A82	MEDDRA-PT-ID E32 10053613
A83	LLT E32 Delayed type hypersensitivity
A84	LLT-ID E32 10012210
A85	CUI E35 C2609414
A86	UMLS-Preferred-Name E35 Acute kidney injury
A87	MEDDRA-PT E35 Acute kidney injury
A88	MEDDRA-PT-ID E35 10069339
A89	flag E37 duplicate
A90	CUI E37 C0853813
A91	UMLS-Preferred-Name E37 Local reaction
A92	MEDDRA-PT E37 Local reaction
A93	MEDDRA-PT-ID E37 10024769
A94	CUI E20 C0020517
A95	UMLS-Preferred-Name E20 Hypersensitivity
A96	MEDDRA-PT E20 Hypersensitivity
A97	MEDDRA-PT-ID E20 10020751
A98	LLT E20 Hypersensitivity reaction
A99	LLT-ID E20 10020756
A100	CUI E21 C0020517
A101	UMLS-Preferred-Name E21 Hypersensitivity
A102	MEDDRA-PT E21 Hypersensitivity
A103	MEDDRA-PT-ID E21 10020751
A104	LLT E21 Hypersensitivity reaction
A105	LLT-ID E21 10020756
A106	CUI E41 C2609414
A107	UMLS-Preferred-Name E41 Acute kidney injury
A108	MEDDRA-PT E41 Acute kidney injury
A109	MEDDRA-PT-ID E41 10069339
